0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Fluorouracil-Floxuridine Controversy

Charles G. Moertel, MD; Richard J. Reitemeier, MD
JAMA. 1967;201(10):780. doi:10.1001/jama.1967.03130100078027.
Text Size: A A A
Published online

To the Editor:—  Over the past five or more years, a vast expenditure of funds, both federal and private, and considerable investigator time have been devoted to the study of floxuridine (FUDR). The most intense study and the greatest controversy have revolved about the effectiveness of this chemotherapeutic agent in the palliative treatment of advanced carcinoma of the large bowel. Recently, these efforts reached their culmination in the almost simultaneous publication of the results obtained by two large cooperative groups. Each group administered the drug by the intravenous injection technique, and each stated their results were evaluated by objective criteria. The Central Region of the Clinical Drug Evaluation Program1 made a strong plea for further use of floxuridine in colonic cancer with their astonishing objective regression rate of 59%. Perplexing in contrast is the 4% regression rate reported by the Eastern Cooperative Group in Solid Tumor Chemotherapy.2 This

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();